原发性骨质疏松症诊疗指南（2017）

doi:10.3969/j.issn.1007-9572.2017.00.118

摘要/Abstract

中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南（2017）[J]. 中国全科医学, 2017, 20(32): 3963-3982. DOI: 10.3969/j.issn.1007-9572.2017.00.118.

［1］ Consensus development conference：diagnosis，prophylaxis，and treatment of osteoporosis［J］．Am J Med，1993，94：646-650．
［2］ NIH Consensus Development Panel on Osteoporosis Prevention ，Diagnosis，and Therapy，March 7-29，2000：Highlights of the Conference［J］．South Med J，2001，94：569-573．
［3］ Glaser DL，Kaplan FS．Osteoporosis．Definition and clinical presentation［J］．Spine（Phila Pa 1976），1997，22：12S-16S．
［4］ Riggs BL，Wahner HW，Dunn WL，et al．Differential changes in bone mineral density of the appendicular and axial skeleton with aging：relationship to spinal osteoporosis［J］．J Clin Invest，1981，67：328-335．
［5］中华人民共和国国家统计局．中国统计年鉴［M］．北京：中国统计出版社，2015．
［6］中国健康促进基金会骨质疏松防治中国白皮书编委会．骨质疏松症中国白皮书［J］．中华健康管理学杂志，2009，3：148-154．
［7］ Siris ES，Adler R，Bilezikian J，et al．The clinical diagnosis of osteoporosis：a position statement from the National Bone Health Alliance Working Group［J］．Osteoporos Int，2014，25：1439-1443．
［8］ Xu L，Cummings SR，Qin MW，et al．Vertebral fractures in Beijing，China：the Beijing Osteoporosis Project［J］．J Bone Miner Res，2000，15：2019-2025．
［9］ Xu L，Lu A，Zhao X，et al．Very low rates of hip fracture in Beijing，People's Republic of China the Beijing Osteoporosis Project［J］．Am J Epidemiol，1996，144：901-907．
［10］ Xia WB，He SL，Xu L，et al．Rapidly increasing rates of hip fracture in Beijing，China［J］．J Bone Miner Res，2012，27：125-129．
［11］ Tian FM，Zhang L，Zhao HY，et al．An increase in the incidence of hip fractures in Tangshan，China［J］．Osteoporos Int，2014，25：1321-1325．
［12］ Wang J，Wang Y，Liu WD，et al．Hip fractures in Hefei，China：the Hefei osteoporosis project［J］．J Bone Miner Metab，2014，32：206-214．
［13］ Si L，Winzenberg TM，Jiang Q，et al．Projection of osteoporosis related fractures and costs in China：2010-2050［J］．Osteoporos Int，2015，26：1929-1937．
［14］ Melton LR，Chrischilles EA，Cooper C，et al．Perspective．How many women have osteoporosis?［J］．J Bone Miner Res，1992，7：1005-1010．
［15］ Cauley JA．The determinants of fracture in men［J］．J Musculoskelet Neuronal Interact，2002，2：220-221．
［16］ Keene GS，Parker MJ，Pryor GA．Mortality and morbidity after hip fractures［J］．BMJ，1993，307：1248-1250．
［17］ Osnes EK，Lofthus CM，Meyer HE，et al．Consequences of hip fracture on activities of daily life and residential needs［J］．Osteoporos Int，2004，15：567-574．
［18］ Wang O，Hu Y，Gong S，et al．A survey of outcomes and management of patients post fragility fractures in China［J］．Osteoporos Int，2015，26：2631-2640．
［19］ Curtis EM，Moon RJ，Dennison EM，et al．Recent advances in the pathogenesis and treatment of osteoporosis［J］．Clin Med（Lond），2015，15：s92-s96．
［19］ Walsh MC，Choi Y．Biology of the RANKL－RANK-OPG system in immunity，bone，and beyond［J］．Front Immunol，2014，5：511．
［21］ Franceschi C，Campisi J．Chronic inflammation（inflammaging）and its potential contribution to age-associated diseases［J］．J Gerontol A Biol Sci Med Sci，2014，69：S4-S9．
［22］ Starup-Linde J，Vestergaard P．Management of endocrine disease：diabetes and osteoporosis：cause for concern?［J］．Eur J Endocrinol，2015，173：R93-R99．
［23］ Feng J，Liu S，Ma S，et al．Protective effects of resveratrol on postmenopausal osteoporosis：regulation of SIRT1-NF-kappa B signaling pathway［J］．Acta Biochim Biophys Sin（Shanghai），2014，46：1024-1033．
［24］ Orimo H，Nakamura T，Hosoi T，et al．Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary［J］．Arch Osteoporos，2012，7：3-20．
［25］ Schulman RC，Weiss AJ，Mechanick JI．Nutrition，bone，and aging：an integrative physiology approach［J］．Curr Osteoporos Rep，2011，9：184-195．
［26］ Cosman F，de Beur SJ，Leboff MS，et al．Clinician's guide to prevention and treatment of osteoporosis［J］．Osteoporos Int，2014，25：2359-2381．
［27］ International Osteoporosis Foundation．IOF One－minute osteoporosis risk test［EB/OL］．［2017-08-25］．https：//www．iofbonehealth．org/iof-one-minute-osteoporosis-risk-test．
［28］ Nayak S，Edwards DL，Saleh AA，et al．Systematic review and meta－analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density［J］．Osteoporos Int，2015，26：1543-1554．
［29］ Centre for Metabolic Bone Diseases，University of Sheffield．Fracture risk assessment tool［EB/OL］．Sheffield，SYT：［2017-08-25］．http：//www．sheffield．ac．uk/FRAX/tool．aspx? country=2．
［30］ Kanis JA，Harvey NC，Cooper C，et al．A systematic review of intervention thresholds based on FRAX：A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation［J］．Arch Osteoporos，2016，11：25．
［31］ Kanis JA，Mccloskey EV，Johansson H，et al．European guidance for the diagnosis and management of osteoporosis in postmenopausal women［J］．Osteoporos Int，2013，24：23-57．
［32］ Zhang ZM，Qu YN，Sheng ZF，et al．How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women［J］．Endocrine，2014，45：195-197．
［33］ Lin J，Yang Y，Fei Q，et al．Validation of three tools for identifying painful new osteoporotic vertebral fractures in older Chinese men：bone mineral density，Osteoporosis Self-Assessment Tool for Asians，and fracture risk assessment tool［J］．Clin Interv Aging，2016，11：461-469．
［34］ Cheung E，Cheung CL，Kung AW，et al．Possible FRAX－based intervention thresholds for a cohort of Chinese postmenopausal women［J］．Osteoporos Int，2014，25：1017-1023．
［35］中华医学会骨质疏松和骨矿盐疾病分会．原发性骨质疏松症诊治指南（2011 年）［J］．中华骨质疏松和骨矿盐疾病杂志，2011，4：2-17．
［36］ Myers AH，Young Y，Langlois JA．Prevention of falls in the elderly［J］．Bone，1996，18：87S-101S．
［37］ Li F，Eckstrom E，Harmer P，et al．Exercise and Fall Prevention：Narrowing the Research-to-Practice Gap and Enhancing Integration of Clinical and Community Practice［J］．J Am Geriatr Soc，2016，64：425-431．
［38］ Borgstrom F，Lekander I，Ivergard M，et al．The International Costs and Utilities Related to Osteoporotic Fractures Study（ICUROS）—quality of life during the first 4 months after fracture［J］．Osteoporos Int，2013，24：811-823．
［39］ Peasgood T，Herrmann K，Kanis JA，et al．An updated systematic review of Health State Utility Values for osteoporosis related conditions［J］．Osteoporos Int，2009，20：853-868．
［40］ Marques A，Lourenco O，Da SJ．The burden of osteoporotic hip fractures in Portugal：costs，health related quality of life and mortality［J］．Osteoporos Int，2015，26：2623-2630．
［41］国务院办公厅．中国防治慢性病中长期规划（2017—2025年）［EB/OL］．（2017-02-14）［2017-08-25］．http：//www．gov．cn/ zhengce/ content/2017-02/14/content_5167886．htm．
［42］ Shepherd JA，Schousboe JT，Broy SB，et al．Executive Summary of the 2015 ISCD Position Development Conference on Advanced Measures From DXA and QCT：Fracture Prediction Beyond BMD［J］．J Clin Densitom，2015，18：274-286．
［43］ Engelke K，Adams JE，Armbrecht G，et al．Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults：the 2007 ISCD Official Positions［J］．J Clin Densiton，2008，11：123-162．
［44］ Genant HK，Wu CY，van Kuijk C，et al．Vertebral fracture assessment using a semiquantitative technique［J］．J Bone Miner Res，1993，8：1137-1148．
［45］ Hu WW，Zhang Z，He JW，et al．Establishing reference intervals for bone turnover markers in the healthy shanghai population and the relationship with bone mineral density in postmenopausal women［J］．Int J Endocrinol，2013，2013：513925．DOI：10．1155/2013/513925．
［46］ Gao C，Qiao J，Li SS，et al．The levels of bone turnover markers 25（OH）D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China［J］．Osteoporos Int，2017，28：211-218．
［47］ Li M，Li Y，Deng WM，et al．Chinese Bone Turnover Marker Study：reference ranges for C-terminal telope-ptide of type I collagen and procollagen I N-terminal peptide by age and gender［J］．PLoS One，2014，9：e103841．doi：10．1371/journal．pone．0103841．
［48］ Li M，Lv F，Zhang ZL，et al．Establishment of a normal reference value of parathyroid hormone in a large healthy Chinese population and evaluation of its relation to bone turnover and bone mineral density［J］．Osteoporos Int，2016，27：1907-1916．
［49］中国营养学会．中国居民膳食指南（2016）［M］．北京：人民卫生出版社，2016．
［50］ Holick MF．Vitamin D deficiency［J］．New Engl J Med，2007，357：266-281．
［51］中国营养学会．中国居民膳食营养素参考摄入量速查手册［M］．北京：中国标准出版社，2014．
［52］ Larsen ER，Mosekilde L，Foldspang A．Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents：a pragmatic population-based 3-year intervention study［J］．J Bone Miner Res，2004，19：370-378．
［53］ Lu H，Zhang Z，Ke Y，et al．High prevalence of vitamin D insufficiency in China：relationship with the levels of parathyroid hormone and markers of bone turnover［J］．PLoS One，2012，7：e47264．doi：10．1371/journal．pone．0047264．
［54］ Ning Z，Song S，Miao L，et al．High prevalence of vitamin D deficiency in urban health checkup population［J］．Clin Nutr，2016，35：859-863．
［55］ Zhao J，Xia W，Nie M，et al．The levels of bone turnover markers in Chinese postmenopausal women：Peking Vertebral Fracture Study［J］．Menopause，2011，18：1237-1243．
［56］ Smith H，Anderson F，Raphael H，et al．Effect of annual intramuscular vitamin D on fracture risk in elderly men and women—a population-based，randomized，double-blind，placebo controlled trial［J］．Rheumatology（Oxford），2007，46：1852-1857．
［57］ Sanders KM，Stuart AL，Williamson EJ，et al．Annual high－dose oral vitamin D and falls and fractures in older women：a randomized controlled trial［J］．JAMA，2010，303：1815-1822．
［58］ Russell RG，Watts NB，Ebetino FH，et al．Mechanisms of action of bisphosphonates：similarities and differences and their potential influence on clinical efficacy［J］．Osteoporos Int，2008，19：733-759．
［59］ Russell RG．Bisphosphonates：the first 40 years［J］．Bone，2011，49：2-19．
［60］ Bone HG，Hosking D，Devogelaer JP，et al．Ten years' experience with alendronate for osteoporosis in postmenopausal women［J］．New Engl J Med，2004，350：1189-1199．
［61］ Lyles KW，Colon-Emeric CS，Magaziner JS，et al．Zoledronic acid and clinical fractures and mortality after hip fracture［J］．New Engl J Med，2007，357：1799-1809．
［62］ Mcclung MR，Geusens P，Miller PD，et al．Effect of risedronate on the risk of hip fracture in elderly women．Hip Intervention Program Study Group［J］．New Engl J Med，2001，344：333-340．
［63］ Chesnut CR，Skag A，Christiansen C，et al．Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis［J］．J Bone Miner Res，2004，19：1241-1249．
［64］ Harris ST，Watts NB，Jackson RD，et al．Four－year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis：three years of blinded therapy followed by one year of open therapy［J］．Am J Med，1993，95：557-567．
［65］ Gu JM，Wang L，Lin H，et al．The efficacy and safety of weekly 35－mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia：1-year data［J］．Acta Pharmacol Sin，2015，36：841-846．
［66］ Zhang ZL，Liao EY，Xia WB，et al．Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women：a 6-month，randomized，openlabel，active-comparator-controlled study with a 6-month extension［J］．Osteoporos Int，2015，26：2365-2374．
［67］ Khan AA，Morrison A，Hanley DA，et al．Diagnosis and management of osteonecrosis of the jaw：a systematic review and international consensus［J］．J Bone Miner Res，2015，30：3-23．
［68］ Ruggiero SL，Dodson TB，Assael LA，et al．American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate－related osteonecrosis of the jaws—2009 update［J］．J Oral Maxillofac Surg，2009，67：2-12．
［69］ Hellstein JW，Adler RA，Edwards B，et al．Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis：executive summary of recommendations from the American Dental Association Council on Scientific Affairs［J］．J Am Dent Assoc，2011，142：1243-1251．
［70］ Shane E，Burr D，Abrahamsen B，et al．Atypical subtrochanteric and diaphyseal femoral fractures：second report of a task force of the American Society for Bone and Mineral Research［J］．J Bone Miner Res，2014，29：1-23．
［71］ Ding Y，Zeng JC，Yin F，et al．Multicenter study on observation of acute－phase responses after infusion of Zoledronic Acid 5 mg in Chinese women with postmenopausal osteoporosis［J］．Orthop Surg，2017，9：282-287．
［72］ Chesnut CR，Silverman S，Andriano K，et al．A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis：the prevent recurrence of osteoporotic fractures study．PROOF Study Group［J］．Am J Med，2000，109：267-276．
［73］ Chesnut CR，Azria M，Silverman S，et al．Salmon calcitonin：a review of current and future therapeutic indications［J］．Osteoporos Int，2008，19：479-491．
［74］ Karachalios T，Lyritis GP，Kaloudis J，et al．The effects of calcitonin on acute bone loss after pertrochanteric fractures．A prospective，randomised trial［J］．J Bone Joint Surg Br，2004，86：350-358．
［75］ Tsakalakos N，Magiasis B，Tsekoura M，et al．The effect of short－term calcitonin administration on biochemical bone markers in patients with acute immobilization following hip fracture［J］．Osteoporos Int，1993，3：337-340．
［76］ Lyritis GP，Ioannidis GV，Karachalios T，et al．Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures：a prospective double-blind，randomized，placebo-controlled clinical study［J］．Clin J Pain，1999，15：284-289．
［77］ Knopp JA，Diner BM，Blitz M，et al．Calcitonin for treating acute pain of osteoporotic vertebral compression fractures：a systematic review of randomized，controlled trials［J］．Osteoporos Int，2005，16：1281-1290．
［78］ Food and Drug Administration．Queations and answers：Changes to the indicated population for miacalcin（calcitonin-salmon）［EB/OL］．（2013- 03- 11）https：//www．fda．gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm388641．htm.
［79］朱汉民，廖二元．鲑鱼降钙素专家讨论会纪实［J］．中华骨质疏松和骨矿盐疾病杂志，2013，6：370-372．
［80］ Cauley JA，Robbins J，Chen Z，et al．Effects of estrogen plus progestin on risk of fracture and bone mineral density：the Women's Health Initiative randomized trial［J］．JAMA，2003，290：1729-1738．
［81］ Rapp SR，Espeland MA，Shumaker SA，et al．Effect of estrogen plus progestin on global cognitive function in postmenopausal women：the Women's Health Initiative Memory Study：a randomized controlled trial［J］．JAMA，2003，289：2663-2672．
［82］ Greenspan SL，Resnick NM，Parker RA．Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women：a randomized controlled trial［J］．JAMA，2003，289：2525-2533．
［83］ Jackson RD，Wactawski-Wende J，Lacroix AZ，et al．Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy：results from the women's health initiative randomized trial［J］．J Bone Miner Res，2006，21：817-828．
［84］ Qaseem A，Forciea MA，Mclean RM，et al．Treatment of low bone density or osteoporosis to prevent fractures in men and women：A Clinical Practice Guideline Update From the American College of Physicians［J］．Ann Intern Med，2017，166：818-839．
［85］ Greenspan SL，Resnick NM，Parker RA．Early changes in biochemical markers of bone turnover are associated with long－term changes in bone mineral density in elderly women on alendronate，hormone replacement therapy，or combination therapy：a three-year，double-blind，placebo-controlled，randomized clinical trial［J］．J Clin Endocrinol Metab，2005，90：2762-2767．
［86］ Ettinger B，Black DM，Mitlak BH，et al．Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene：results from a 3-year randomized clinical trial．Multiple Outcomes of Raloxifene Evaluation（MORE）Investigators［J］．JAMA，1999，282：637-645．
［87］ Cummings SR，Eckert S，Krueger KA，et al．The effect of raloxifene on risk of breast cancer in postmenopausal women：results from the MORE randomized trial．Multiple Outcomes of Raloxifene Evaluation［J］．JAMA，1999，281：2189-2197．
［88］ Vogel VG，Costantino JP，Wickerham DL，et al．Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes：the NSABP Study of Tamoxifen and Raloxifene（STAR）P- 2 trial［J］．JAMA，2006，295：2727-2741．
［89］ Neer RM，Arnaud CD，Zanchetta JR，et al．Effect of parathyroid hormone（1- 34）on fractures and bone mineral density in postmenopausal women with osteoporosis［J］．New Engl J Med，2001，344：1434-1441．
［90］ Jiang Y，Zhao JJ，Mitlak BH，et al．Recombinant human parathyroid hormone（1-34）［teriparatide］improves both cortical and cancellous bone structure［J］．J Bone Miner Res，2003，18：1932-1941．
［91］ Vahle JL，Long GG，Sandusky G，et al．Bone neoplasms in F344 rats given teriparatide［rhPTH（1-34）］are dependent on duration of treatment and dose［J］．Toxicol Pathol，2004，32：426-438．
［92］ Vahle JL，Sato M，Long GG，et al．Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone（1-34）for 2 years and relevance to human safety［J］．Toxicol Pathol，2002，30：312-321．
［93］ Andrews EB，Gilsenan AW，Midkiff K，et al．The US postmarketing surveillance study of adult osteosarcoma and teriparatide：study design and findings from the first 7 years［J］．J Bone Miner Res，2012，27：2429-2437．
［94］ Meunier PJ，Roux C，Seeman E，et al．The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis［J］．New Engl J Med，2004，350：459-468．
［95］ European Medicines Agency．EMEA recommends changes in the product information for Protelos/Osseor due to the risk of severe hypersensitivity reactions［EB/OL］．［2017-08-25］．http：//www．ema．europa．eu/docs/en _GB/document _ library/Press _ release/2009/11/WC500015592．pdf．
［96］ Pernicova I，Middleton ET，Aye M．Rash，strontium ranelate and DRESS syndrome put into perspective．European Medicine Agency on the alert［J］．Osteoporos Int，2008，19：1811-1812．
［97］ European Medicnes Agency．Recommendation to restrict the use of Protelos/Osseor（strontium ranelate）［EB/OL］．［2017-08-25］．http：///www．ema．europa．eu/ema/index．jsp? curl=pages/news _ and _ events/news/2013/04/news _ detail _001774．jsp＆mid=WC0b01ac058001d126．
［98］ Abrahamsen B，Grove EL，Vestergaard P．Nationwide registry based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate［J］．Osteoporos Int，2014，25：757-762．
［99］ Bischoff-Ferrari HA，Dawson-Hughes B，Staehelin HB，et al．Fall prevention with supplemental and active forms of vitamin D：a meta-analysis of randomised controlled trials［J］．BMJ，2009，339：b3692．
［100］ Jiang Y，Zhang ZL，Zhang ZL，et al．Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis：a multicenter，randomized，double-blinded，double-dummy，positive drug-controlled clinical trial［J］．Clin Interv Aging，2014，9：121-127．
［101］ Cummings SR，San MJ，Mcclung MR，et al．Denosumab for prevention of fractures in postmenopausal women with osteoporosis［J］．New Engl J Med，2009，361：756-765．
［102］ Camacho PM，Petak SM，Binkley N，et al．American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis－2016［J］．Endocr Pract，2016，22：1-42．
［103］ Goldhahn J，Feron JM，Kanis J，et al．Implications for fracture healing of current and new osteoporosis treatments：an ESCEO consensus paper［J］．Calcif Tissue Int，2012，90：343-353．
［104］ Li YT，Cai HF，Zhang ZL．Timing of the initiation of bisphosphonates after surgery for fracture healing：a systematic review and meta-analysis of randomized controlled trials［J］．Osteoporos Int，2015，26：431-441．
［105］ Hadji P，Zanchetta JR，Russo L，et al．The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures［J］．Osteoporos Int，2012，23：2141-2150．
［106］ Finkelstein JS，Hayes A，Hunzelman JL，et al．The effects of parathyroid hormone，alendronate，or both in men with osteoporosis［J］．New Engl J Med，2003，349：1216-1226．
［107］ Mcguire R．AAOS Clinical Practice Guideline：the treatment of symptomatic osteoporotic spinal compression fractures［J］．J Am Acad Orthop Surg，2011，19：183-184．
［108］ Palacios S，Mejia A．Antiresorptives and anabolic therapy in sequence or combination for postmenopausal osteoporosis［J］．Climacteric，2015，18：453-455．
［109］夏维波．骨质疏松症的联合治疗与序贯治疗［J］．中华骨质疏松和骨矿盐疾病杂志，2011，4：73-81．
［110］ Cosman F．Anabolic and antiresorptive therapy for osteoporosis：combination and sequential approaches［J］．Curr Osteoporos Rep，2014，12：385-395．
［111］ Finkelstein JS，Wyland JJ，Lee H，et al．Effects of teriparatide，alendronate，or both in women with postmenopausal osteoporosis［J］．J Clin Endocrinol Metab，2010，95：1838-1845．
［112］ Cosman F，Eriksen EF，Recknor C，et al．Effects of intravenous zoledronic acid plus subcutaneous teriparatide［rhPTH（1-34）］in postmenopausal osteoporosis［J］．J Bone Miner Res，2011，26：503-511．
［113］ Deal C，Omizo M，Schwartz EN，et al．Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis：results from a 6-month double-blind placebo-controlled trial［J］．J Bone Miner Res，2005，20：1905-1911．
［114］ Cosman F，Nieves J，Woelfert L，et al．Parathyroid hormone added to established hormone therapy：effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal［J］．J Bone Miner Res，2001，16：925-931．
［115］ Rittmaster RS，Bolognese M，Ettinger MP，et al．Enhancement of bonemass in osteoporotic women with parathyroid hormone followed by alendronate［J］．J Clin Endocrinol Metab．2000; 85：2129-2134．
［116］ Shi XL，Li CW，Wan QZ，et al．Drynaria total flavonoids decrease cathepsin K expression in ovariectomized rats［J］．Genet Mol Res，2014，13：4311-4319．
［117］ Ang ES，Yang X，Chen H，et al．Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL－induced NF-kappa B and ERK activation［J］．FEBS Lett，2011，585：2755-2762．
［118］ Xu T，Wang L，Tao Y，et al．The Function of Naringin in Inducing Secretion of Osteoprotegerin and Inhibiting Formation of Osteoclasts［J］．Evid Based Complement Alternat Med，2016，2016：8981650．
［119］ Mok SK，Chen WF，Lai WP，et al．Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor－dependent osteoblastic functions in UMR 106 cells［J］．Br J Pharmacol，2010，159：939-949．
［120］ Zhu HM，Qin L，Garnero P，et al．The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis［J］．Osteoporos Int，2012，23：1317-1327．
［121］ Liu M，Zhong C，He RX，et al．Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis［J］．Chin Med J（Engl），2012，125：1784-1789．
［122］ Ouyang L，Zhang Q，Ruan X，et al．Treatment effect of Bushen Huayu extract on postmenopausal osteoporosis in vivo［J］．Exp Ther Med，2014，7：1687-1690．
［123］ Chen G，Wang C，Wang J，et al．Antiosteoporotic effect of icariin in ovariectomized rats is mediated via the Wnt/betacatenin pathway［J］．Exp Ther Med，2016，12：279-287．
［124］ Yang YP，Shuai B，Shen L，et al．Effect of Qing'e formula on circulating sclerostin levels in patients with postmenopausal osteoporosis［J］．J Huazhong Univ Sci Technolog Med Sci，2015，35：525-530．
［125］ Shuai B，Shen L，Zhu R，et al．Effect of Qing'e formula on the in vitro differentiation of bone marrow-derived mesenchymal stem cells from proximal femurs of postmenopausal osteoporotic mice［J］．BMC Complement Altern Med，2015，15：250．
［126］ Shuai B，Zhu R，Yang YP，et al．Positive effects of Qing'e Pill on trabecular microarchitecture and its mechanical properties in osteopenic ovariectomised mice［J］．Chin J Integr Med，2016，Epub ahead of print．doi：10．1007/s11655-016-2604-0．
［127］国家食品药品监督管理局药品评审中心．中药新药临床研究指导原则［M］．北京：中国医药科技出版社，2015：100．
［128］ Roghani T，Torkaman G，Movasseghe S，et al．Effects of shortterm aerobic exercise with and without external loading on bone metabolism and balance in postmenopausal women with osteoporosis［J］．Rheumatol Int，2013，33：291-298．
［129］ Rubin CT，Donahue HJ，Rubin JE，et al．Optimization of electric field parameters for the control of bone remodeling：exploitation of an indigenous mechanism for the prevention of osteopenia［J］．J Bone Miner Res，1993，8：S573-S581．
［130］ Saggini R，Di Stefano A，Saggini A，et al．Clinical application of shock wave therapy in musculoskeletal disorders：part I［J］．J Biol Regul Homeost Agents，2015，29：533-545．
［131］ Oliveira LC，Oliveira RG，Pires-Oliveira DA．Effects of whole body vibration on bone mineral density in postmenopausal women：a systematic review and meta-analysis［J］．Osteoporos Int，2016，27：2913-2933．
［132］ Schandelmaier S，Kaushal A，Lytvyn L，et al．Low intensity pulsed ultrasound for bone healing：systematic review of randomized controlled trials［J］．BMJ，2017，356：j656．
［133］ Caro JJ，Ishak KJ，Huybrechts KF，et al．The impact of compliance with osteoporosis therapy on fracture rates in actual practice［J］．Osteoporos Int，2004，15：1003-1008．
［134］ Rabenda V，Reginster JY．Overcoming problems with adherence to osteoporosis medication［J］．Expert Rev Pharmacoecon Outcomes Res，2010，10：677-689．
［135］ Rabenda V，Bruyere O，Reginster JY．Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation：a meta-regression［J］．Osteoporos Int，2011，22：893-901．
［136］ Compston J．Monitoring osteoporosis treatment［J］．Best Pract Res Clin Rheumatol，2009，23：781-788．
［137］ Cummings SR，Karpf DB，Harris F，et al．Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs［J］．Am J Med，2002，112：281-289．
［138］ Sarkar S，Mitlak BH，Wong M，et al．Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy［J］．J Bone Miner Res，2002，17：1-10．
［139］ Austin M，Yang YC，Vittinghoff E，et al．Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures［J］．J Bone Miner Res，2012，27：687-693．
［140］ Chen P，Miller PD，Delmas PD，et al．Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide－treated postmenopausal women with osteoporosis［J］．J Bone Miner Res，2006，21：1785-1790．
［141］ Gluer CC，Blake G，Lu Y，et al．Accurate assessment of precision errors：how to measure the reproducibility of bone densitometry techniques［J］．Osteoporos Int，1995，5：262-270．
［142］ ISCD．2007 Offical Positions of the International Society for Clinical Densitometry［EB/OL］．［2017-08-25］．http：//www．iscd．org/Visitors/positions/OfficialPositionsText．cfm．
［143］ Delmas PD．Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs［J］．Osteoporos Int，2000，11：S66-S76．
［144］ Eastell R，Barton I，Hannon RA，et al．Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate［J］．J Bone Miner Res，2003，18：1051-1056．
［145］ Bauer DC，Black DM，Garnero P，et al．Change in bone turnover and hip，non-spine，and vertebral fracture in alendronate-treated women：the fracture intervention trial［J］．J Bone Miner Res，2004，19：1250-1258．
［146］ Sarkar S，Reginster JY，Crans GG，et al．Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk［J］．J Bone Miner Res，2004，19：394-401．
［147］张雪，杨柠溪．英美分级诊疗实践及对我国的启示［J］．医学与哲学，2015，36：78-81．
［148］ Brixi H，Mu Y，Targa B，et al．Engaging sub－national governments in addressing health equities：challenges and opportunities in China's health system reform［J］．Health Policy Plan，2013，28：809-824．
［149］国务院办公厅，国务院办公厅关于推进分级诊疗制度建设的指导意见［EB/OL］．［2016-10-31］．http：//www．gov．cn/zhengce/content/2015-09/11/content_10158．htm.
［150］方少华．全民医保背景下实现分级诊疗的路径研究［J］．卫生经济研究，2014，34：18-21．
［151］国家卫生和计划生育委员会：糖尿病分级诊疗技术方案［EB/OL］．［2016- 10- 31］．http：//www．nhfpc．gov．cn/ewebeditor/uploadfile/2015/12/20151201154944649．doc．
［152］余红星，冯友梅，付旻，等．医疗机构分工协作的国际经验及启示—基于英国、德国、新加坡和美国的分析［J］．中国卫生政策研究，2014，7：10-15．
［153］ IOF：Clinical Guidance on Management of Osteoporosis2012［S/OL］．［2017- 08- 25］．http：//www．iofbonehealth. org/sites/default/files/PDFs/National% 20 Guidelines/Malaysia _ CG _Mgmt_Osteoporosis_2012-0912-final．pdf．
［154］ Yip WC，Hsiao WC，Chen W，et al．Early appraisal of China's huge and complex health-care reforms［J］．Lancet，2012，379：833-842．

[1]	秦凤银, 张绮珊, 赖锦佳, 黄奕敏, 韩郭茵, 孙兴兰, 王芬, 谭益冰. 广东省社区居民脑卒中高危筛查意向的现状及影响因素研究[J]. 中国全科医学, 2023, 26(34): 4283-4289.
[2]	刘伟娜, 葛海燕, 马静, 曹琴英, 白星宇, 崔士芳, 乔彦霞. 脐血维生素A和维生素E水平与早产儿发生呼吸窘迫综合征的关系研究[J]. 中国全科医学, 2023, 26(33): 4152-4158.
[3]	李纪新, 邱林杰, 任燕, 王文茹, 李美洁, 张晋. 膳食炎症指数与超重和肥胖及腹型肥胖关系的Meta分析[J]. 中国全科医学, 2023, 26(32): 4089-4097.
[4]	马丽媛, 王增武, 樊静, 胡盛寿. 《中国心血管健康与疾病报告2022》要点解读[J]. 中国全科医学, 2023, 26(32): 3975-3994.
[5]	李雨荆, 晋一超, 陈醒, 嵇梦颖, 戴辉华. 服用他莫昔芬的乳腺癌患者宫腔镜检出子宫内膜病变的危险因素研究[J]. 中国全科医学, 2023, 26(32): 4026-4030.
[6]	陈静, 邹涛, 赵丹青, 肖子文, 吴献青, 中华医学会心身医学分会围产期精神障碍协作组. 围产期精神障碍筛查与诊治专家共识[J]. 中国全科医学, 2023, 26(28): 3463-3470.
[7]	任延峰, 刘世蒙, 陶颖, 陈英耀. 抑郁症患者药物治疗偏好的系统综述：基于离散选择实验和优劣尺度法[J]. 中国全科医学, 2023, 26(28): 3559-3564.
[8]	张笃飞, 陈仁伟, 莫泽来, 羊玲, 王亚洲, 王海凡. 海南省新生儿先天性心脏病筛查-诊断-评估适宜技术的应用研究[J]. 中国全科医学, 2023, 26(25): 3170-3177.
[9]	任园园, 程功, 蒋红英, 王依阳, 陈亮, 赵慧, 梁宸源. 冠心病患者冠状动脉钙化及其严重程度的影响因素研究[J]. 中国全科医学, 2023, 26(24): 2980-2985.
[10]	曾令烽, 杨伟毅, 梁桂洪, 肖萧, 罗明辉, 潘建科, 韩燕鸿, 黄和涛, 赵金龙, 徐南俊, 周光辉, 张献泉, 梁伟雄, 欧爱华, 刘军, 广东省中医药学会骨关节退变与损伤专业委员会. 骨质疏松高危人群中医症状评估专家问卷调查和结果研究[J]. 中国全科医学, 2023, 26(24): 2986-2991.
[11]	中华预防医学会更年期保健分会, 中国人体健康科技促进会妇科内分泌和生育力促进专委会, 北京中西医结合学会更年期专业委员会. 绝经相关失眠临床管理中国专家共识[J]. 中国全科医学, 2023, 26(24): 2951-2958.
[12]	王瑞, 王小梅, 彭国庆, 余欢, 王思涵, 夏瑾. 成人癌症恶病质的筛查评估与干预治疗——基于《成人癌症恶病质：ESMO临床实践指南》解读[J]. 中国全科医学, 2023, 26(23): 2823-2829.
[13]	左旭, 黄招兰, 陆彪. 35~64岁自报非高血压人群首次血压测量与非同日3次血压测量结果的差异及其影响因素分析[J]. 中国全科医学, 2023, 26(22): 2771-2777.
[14]	孟凡, 董敏洁, 郭瑾, 许松涛, 严薇, 顾俊, 陈忆蓉, 杨乘, 王军, 夏丽芳, 陈俊, 富灵杰. 社区老年人骨质疏松患病情况及全科防控策略[J]. 中国全科医学, 2023, 26(22): 2778-2784.
[15]	许海娜, 安苗苗, 朱焱, 吴春艳, 冉利梅. 围绝经期体检女性肌肉和脂肪组织与骨密度的关系研究[J]. 中国全科医学, 2023, 26(21): 2626-2631.

原发性骨质疏松症诊疗指南（2017）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

留言